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Background. We evaluated the impact of opioid substitution therapy (OST) on the completion, adherence, efficacy, and safety 
of the 3-direct-acting antiviral regimen of ombitasvir, paritaprevir (identified by AbbVie and Enanta) co-dosed with ritonavir, and 
dasabuvir ± ribavirin among patients infected with hepatitis C virus (HCV) genotype (GT) 1, with or without compensated cirrhosis. 
Methods. Data were pooled from GT1-infected patients enrolled in 12 phase II/III/IIIb clinical trials and categorized by use of 
OST. Patients with ongoing drug use were excluded. HCV treatment completion, treatment adherence (≥90%), sustained virologic 
response at post-treatment week 12 (SVR12), and adverse events were assessed. 
Results. Of 4747 patients, 3% (n = 149) received OST. Among patients receiving OST vs those not receiving OST, 82% (n = 122) 
vs 52% (n = 2409) had GT1a infection; 76% (n = 113) vs 61% (n = 2792) were treatment naïve; and 17% (n = 25) vs 18% (n = 830) 
had cirrhosis, respectively. The proportion of patients completing HCV treatment did not differ between those receiving and not 
receiving OST (97% [n = 144] vs 98% [n = 4510], respectively), whereas adherence to treatment was reduced in patients receiving 
vs those not receiving OST (88% [n = 105] vs 97% [n = 4057], respectively). SVR12 was similar between patients receiving and not 
receiving OST (94% [n = 140] vs 96% [n = 4405], respectively; P = .273). Treatment was well tolerated. 
Conclusions. Although treatment adherence was lower in patients receiving OST vs those not receiving OST, treatment com-
pletion and SVR12 were similar between groups. These data support the use of direct-acting antiviral therapies in patients receiving 
OST.
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In many countries, the majority of new and existing cases of 
hepatitis C virus (HCV) infection occur among people who 
inject drugs (PWID), currently or formerly [1]. This includes 
people receiving opioid substitution therapy (OST) for the 
management of opioid dependence. The availability of simple 
and well-tolerated direct-acting antiviral (DAA) therapies with 
the ability to cure >95% of patients offer an unprecedented 
opportunity to reverse the rising burden of advanced liver dis-
ease among people receiving OST [2]. However, in some set-
tings, people receiving OST are still ineligible [3] or might not 
be considered suitable by practitioners [4] to receive DAAs. 
Concerns about treatment adherence and poorer outcomes 
than in people not receiving OST, and the potential risk of 
re-infection are often cited as reasons for not treating HCV in 
people receiving OST [5].
Post hoc analyses of phase II and III trials of DAA therapy 
have demonstrated that sustained virologic response (SVR) 
is similar in those receiving and not receiving OST [6–13]. In 
the first dedicated clinical trial of DAA therapy among peo-
ple receiving OST, the all-oral 3-DAA regimen of ombitasvir, 
paritaprevir with the pharmacokinetic enhancer ritonavir, 
and dasabuvir in combination with ribavirin was evaluated 
for 12 weeks in 38 participants receiving methadone (n = 19) 
or buprenorphine (n  =  19) OST with HCV genotype (GT) 1 
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(84% GT1a) without cirrhosis [14]. Participants with a posi-
tive urine drug screen for noncannabis drugs at screening were 
excluded. Overall, 97% (37/38) of participants in the study com-
pleted treatment, and 97% (37/38) achieved sustained virologic 
response at post-treatment week 12 (SVR12), with no partici-
pants experiencing virologic failure. However, further data on 
HCV treatment outcomes in people receiving OST are needed.
Ombitasvir, paritaprevir with the pharmacokinetic enhancer 
ritonavir, and dasabuvir with or without ribavirin is approved 
for the treatment of patients with HCV GT1 infection. In clin-
ical trials, ombitasvir/paritaprevir/ritonavir and dasabuvir with 
or without ribavirin demonstrated an SVR12 of ≥94% across 
many patient groups, including those receiving OST [12–22].
The aim of this post hoc analysis was to evaluate the impact 
of OST on treatment completion, adherence, SVR, and safety of 
ombitasvir/paritaprevir/ritonavir and dasabuvir with or with-
out ribavirin in patients with chronic HCV GT1 infection with 
or without decompensated cirrhosis.
METHODS
Study Participants and Design
From September 10, 2012, to April 28, 2016, participants were 
enrolled in 12 international phase II, phase III, and phase IIIb 
studies including SAPPHIRE-I/II (ClinicalTrials.gov identi-
fiers: NCT01716585 and NCT01715415) [12, 13], PEARL-II/
III/IV (NCT01674725, NCT01767116, and NCT01833533) 
[15, 16], TURQUOISE-I/II/III (NCT01939197, NCT01704755, 
and NCT02219503) [17–19], TOPAZ-VA (NCT02442284) [20], 
TOPAZ-I/II (NCT02219490 and NCT02167945) [21, 22], and 
NCT01911845 [14].
Participants with chronic HCV GT1 without cirrhosis were 
treated with ombitasvir/paritaprevir/ritonavir and dasabuvir 
with or without ribavirin for 12 weeks, and patients with com-
pensated cirrhosis were treated with ombitasvir/paritaprevir/
ritonavir and dasabuvir with ribavirin for 12 or 24 weeks or 
without ribavirin for 12 weeks [12–22].
Participants receiving OST (eg, methadone or buprenor-
phine) were eligible for inclusion in 6 of the studies included 
in the analysis. Patients with ongoing drug use were generally 
excluded from these trials based on the results of urine drug 
screens or at the investigator’s discretion [12–22]. Study designs 
and patient inclusion/exclusion criteria have been described 
previously [12–22].
Study End Points
In this analysis, the end points included treatment comple-
tion, adherence (≥90% of doses), SVR12, safety (adverse 
events [AEs], laboratory abnormalities, and serious AEs), and 
re-infection. The analysis population included all randomized 
patients who received ≥1 dose of ombitasvir/paritaprevir/
ritonavir and dasabuvir with or without ribavirin (intent-to-
treat analysis). Treatment completion was defined as ≥77 days 
of treatment for 12-week regimens and ≥154 days for 24-week 
regimens. Adherence was calculated by dividing the number of 
total pills received during therapy (determined by pill counts at 
study visits in weeks 4, 8, 12, and 24 [where applicable]) by the 
total expected number of pills. Patients with missing adherence 
data due to incomplete record of pill counts were excluded from 
adherence analyses. SVR12 was defined as HCV RNA less than 
the lower limit of quantification of 25 IU/mL in serum, meas-
ured by the COBAS TaqMan HCV Test, v2.0 (Roche Molecular 
Systems), at post-treatment week 12. Participants were moni-
tored for relapse/re-infection for 24 to 104 weeks following the 
completion of treatment. Phylogenetic analyses were used to 
distinguish virologic failure from re-infection.
Statistical Analysis
Descriptive statistics, including means, frequencies, and per-
centages (with 95% confidence intervals for SVR12), were 
used to summarize the data. The proportion of participants 
with treatment completion, ≥90% adherence, SVR12, and AEs 
were compared among people receiving and not receiving OST. 
All HCV GT1 subtypes other than GT1a/1b were categorized 
and analyzed as GT1a. Comparisons were made using the chi-
square test to assess the difference of proportions between 2 
groups, except for the comparison between adherence to ribavi-
rin and DAA (ombitasvir/paritaprevir/ritonavir and dasabuvir), 
for which a logistic regression model with random effects was 
used for the paired binary data with missing values. All P val-
ues are 2-sided; a level of .05 was considered statistically signif-
icant. Confidence intervals for SVR12 were constructed using 
the Wilson score method for a binomial proportion. Statistical 
analysis was performed using SAS 9.2 software (SAS Institute 
Inc., Cary, NC).
RESULTS
Participant Characteristics
Of the 4747 patients enrolled and treated across these 12 clin-
ical trials, 3% (n = 149) were receiving OST at enrollment. The 
demographic baseline and clinical characteristics of the study 
participants are shown in Table  1. Compared with those not 
receiving OST, people receiving OST were younger (median 
age, 49 years vs 54 years) and more often male (75% vs 57%), 
infected with HCV GT1a (82% vs 52%), and treatment naïve 
(76% vs 61%). The proportion with cirrhosis was similar in those 
receiving and not receiving OST (17% vs 18%, respectively).
Among people receiving OST, methadone was prescribed 
in 50% (75/149), buprenorphine alone or with naloxone in 
40% (59/149), and other unspecified OST medications in 10% 
(15/149). Among people receiving OST, 14% (n = 21) and 68% 
(n  =  101) were infected with HCV GT1a with and without 
compensated cirrhosis, respectively, and 3% (n  =  4) and 15% 
(n = 23) were infected with HCV GT1b with and without com-
pensated cirrhosis, respectively.
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HCV Treatment Completion
The proportion of patients completing HCV therapy was 97% 
(144/149) in participants receiving OST compared with 98% 
(4510/4598) in those not receiving OST (P  =  .211) (Table  2). 
For the 5 participants receiving OST who discontinued therapy, 
the reasons for discontinuation included AEs (n = 3) and loss 
to follow-up (n = 2). Among the 89 participants not receiving 
OST who discontinued therapy, the reasons for discontinuation 
included AEs (n = 32), virologic failure (n = 13), noncompli-
ance (n  =  5), withdrawn consent (n  =  16), loss to follow-up 
(n = 10), and other (n = 13).
HCV Treatment Adherence
The proportion of participants with ≥90% adherence to all study 
treatment was 88% (105/120) in those receiving OST compared 
with 97% (4057/4173) in those not receiving OST (P  <  .001) 
(Table 2). For participants receiving OST and ombitasvir/par-
itaprevir/ritonavir plus dasabuvir with ribavirin, adherence to 
ribavirin was similar to adherence with ombitasvir/paritaprevir/
ritonavir plus dasabuvir (89% vs 92%; P = .517). Adherence to 
ribavirin was lower than adherence to the DAAs in participants 
not receiving OST (97% vs 99%; P < .001). Among participants 
receiving ribavirin-free therapy, the proportion with ≥90% 
adherence to therapy was 100% (11/11) for those receiving OST 
compared with 98% (1437/1465) in those not receiving OST 
(Table 2).
HCV Treatment Outcomes
The proportion of participants with end-of-treatment response 
among all those receiving ombitasvir/paritaprevir/ritonavir 
Table 1. Baseline Demographic and Clinical Characteristics of Patients 
With Chronic HCV Genotype 1 Receiving Ombitasvir/Paritaprevir/Ritonavir 
and Dasabuvir With or Without Ribavirin, Stratified by Receipt of Opioid 
Substitution Therapy
Characteristic
Receiving  
OST (n = 149)
Not Receiving  
OST (n = 4598)
Male, No. (%) 112 (75) 2639 (57)
Caucasian, No. (%) 140 (94) 4177 (91)
Age, median (range), y 49 (19–69) 54 (18–83)
BMI, median (range), kg/m2 26 (16–45) 26 (16–52)
Geographic region, No. (%)
North America 92 (62) 1968 (43)
Europe 53 (36) 2453 (53)
Australia/New Zealand 0 44 (1)
Asia 0 51 (1)
Tobacco use (current), No. (%)a 108 (72) 1367 (30)
Alcohol use (current), No. (%)b 37 (25) 1368 (30)
History of injecting drug use, No. (%)c
Yes 58 (39) 859 (19)
No 10 (7) 1592 (35)
Missing 81 (54) 2142 (47)
HCV GT1 subtype, No. (%)
1a 122 (82) 2409 (52)
1b 27 (18) 2189 (48)
IFNL3 (IL28B) non-CC genotype, No. (%)d 98 (66) 3568 (78)
Baseline HCV ≥800 000 log10 IU/mL, No. 
(%)e
114 (77) 3526 (77)
Treatment naïve, No. (%) 113 (76) 2792 (61)
HIV infection, No. (%) 18 (12) 271 (6)
Fibrosis stage, No. (%)f
F0–F1 84 (56) 2599 (57)
F2 22 (15) 618 (13)
F3 18 (12) 547 (12)
F4 25 (17) 830 (18)
Therapy
DAA + RBV 138 (93) 3071 (67)
DAA 11 (7) 1527 (33)
Abbreviations: BMI, body mass index; DAA, direct-acting antiviral; GT, genotype; HCV, hep-
atitis C virus; IL28B, interleukin-28B gene; OST, opioid substitution therapy; RBV, ribavirin.
aTobacco use was unknown for 20 patients (0.4%) who were not receiving OST.
bAlcohol use was unknown for 1 (0.7%) and 54 patients (1%) among those receiving OST 
and those not receiving OST, respectively.
cFormer injection drug use information was not collected in 2 of the 12 studies included 
in this analysis.
dIFNL3 genotype was missing for 1 (0.7%) and 20 patients (0.4%) among those receiving 
OST and those not receiving OST, respectively.
eBaseline HCV RNA was missing for 3 patients (0.07%) who were not receiving OST.
fBaseline fibrosis stage was missing for 4 patients (0.09%) who were not receiving OST. 
Fibrosis stage was determined using the results of a liver biopsy, FibroScan, or FibroTest/
aspartate aminotransferase to platelet ratio index.
Table 2. Treatment Completion, Adherence, and Summary of SVR12 and 
Reasons for Non-SVR12 Among Patients With Chronic HCV Genotype 
1 Receiving Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or 
Without Ribavirin, Stratified by Receipt of Opioid Substitution Therapy
Receiving OST
Not Receiving 
OST P Value
Treatment completion, n/N (%)a 144/149 (97) 4510/4598 (98) .211
Treatment adherence, n/N (%)b
Overall treatmentc 105/120 (88) 4057/4173 (97) <.001
DAA + RBV
DAA 114/124 (92) 2855/2893 (99) <.001
RBV 101/113 (89) 2699/2780 (97) <.001
DAA only
DAA 11/11 (100) 1437/1465 (98) .643
SVR12, n/N (%) 140/149 (94) 4405/4598 (96) .273
Reasons for non-SVR12, No. (%)
On-treatment virologic failure 0 25 (0.5)
Premature study drug 
 discontinuation (adverse events)
2 (1) 17 (0.4)
Premature study drug 
 discontinuation (lost to 
follow-up)
2 (1) 8 (0.2)
Virological relapse 2 (1) 75 (2)
Lost to follow-up following com-
pletion of treatment (SVR data 
missing)
3 (2) 48 (1)
Abbreviations: DAA, direct-acting antiviral (ombitasvir/paritaprevir/ritonavir + dasabuvir); 
HCV, hepatitis C virus; OST, opioid substitution therapy; RBV, ribavirin; SVR12, sustained 
virologic response at post-treatment week 12.
aTreatment completion was defined as ≥77 days of treatment for 12-week regimens and 
≥154 days for 24-week regimens.
bAdherence was calculated by dividing the number of total pills received during therapy 
(determined by pill counts at study visits in weeks 4, 8, 12, and 24 [where applicable]) by 
the total expected number of pills.
cOverall treatment adherence included people who had complete adherence data for DAA 
+ RBV therapy (both DAA and RBV) and DAA therapy.
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and dasabuvir with or without ribavirin was 97% (145/149) 
in those receiving OST compared with 98% (4523/4598) in 
those not receiving OST (P  =  .323). The proportion of par-
ticipants with SVR12 among all those receiving ombitasvir/
paritaprevir/ritonavir and dasabuvir with or without ribavirin 
was 94% (140/149) in those receiving OST compared with 96% 
(4405/4598) in those not receiving OST (P = .273). The reasons 
for non-SVR in both those receiving and not receiving OST are 
shown in Table 2. The SVR12 by label-recommended ombitas-
vir/paritaprevir/ritonavir and dasabuvir with or without ribavi-
rin is shown in Figure 1.
Safety
There were no serious DAA-related AEs in patients receiving 
OST, and the proportions of DAA-related AEs leading to dis-
continuation of the study drug were low and similar among 
patients receiving OST and those not receiving OST (Table 3). 
Frequencies of AEs were generally comparable between patients 
receiving OST vs those not receiving OST; nausea and anxiety 
were the only 2 AEs occurring with a frequency ≥5% higher 
in patients receiving OST vs those not receiving OST (Table 4).
HCV Re-infection
HCV re-infection occurred in 7/4747 (0.2%) participants 
included in this analysis who received at least 1 dose of ombitas-
vir/paritaprevir/ritonavir and dasabuvir with or without ribavi-
rin. There was 1 case of HCV re-infection in the period following 
the end of treatment among 149 participants receiving OST. This 
patient relapsed 104 weeks after treatment and was determined 
to be re-infected with an isolate of GT1a that was genetically 
distinct from the one present at baseline before treatment. Six 
cases of HCV re-infection were also observed among 4598 par-
ticipants not receiving OST, of which 5 patients with HCV GT1a 
infection at baseline were re-infected with a genetically distinct 
isolate of GT1a during the post-treatment period. One patient 
infected with GT1b at baseline was re-infected with HCV GT3a 
at post-treatment week 52. Three cases of re-infection occurred 
in patients with HIV-1/HCV coinfection, 2 of whom reported 
high-risk behaviors of unprotected anal intercourse with a sexual 
partner after completion of study drug treatment [19]. Among 
the 7 cases of HCV re-infection, all re-infections occurred dur-
ing the post-treatment period between 8 and 104 weeks after the 
end of treatment (n = 1 at 8 weeks post-treatment, 2 at 12 weeks 
post-treatment, 1 at 24 weeks post-treatment, 1 at 52 weeks 
post-treatment, and 2 at 104 weeks post-treatment).
DISCUSSION
In this post hoc analysis of data from 12 international clinical tri-
als, there was no difference observed in the proportion of patients 
who completed HCV treatment or achieved SVR12 among people 
receiving and not receiving OST treated with ombitasvir/paritap-
revir/ritonavir and dasabuvir with or without ribavirin. However, 
the proportion with ≥90% adherence to therapy was significantly 
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Figure  1. SVR12 in patients receiving and not receiving OST by label-recom-
mended ombitasvir/paritaprevir/ritonavir and dasabuvir with or without riba-
virin. Error bars represent 95% confidence intervals. *No genotype 1b-infected 
patients with cirrhosis receiving OST received the label-recommended therapy. 
Abbreviations: OST, opioid substitution therapy; SVR12, sustained virologic 
response at post-treatment week 12. 
Table  3. Safety Summary Among Patients With Chronic HCV Genotype 1 Receiving Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without 
Ribavirin, Stratified by Receipt of Opioid Substitution Therapy and Receipt of Ribavirin
No. (%)
Receiving OST Not Receiving OST
All
(n = 149) No RBV (n = 11) + RBV (n = 138) All (n = 4598)
No RBV
(n = 1527) + RBV (n = 3071)
Any AE 127 (85) 9 (82) 118 (85) 3596 (78) 991 (65) 2605 (85)
DAA-related AE 98 (66) 6 (55) 92 (67) 2613 (57) 666 (44) 1947 (63)
Serious AE 3 (2) 0 3 (2) 132 (3) 27 (2) 105 (3)
DAA-related serious AE 0 0 0 20 (<1) 4 (<1) 16 (1)
AE leading to D/C 3 (2) 0 3 (2) 37 (1) 5 (<1) 32 (1)
DAA-related AE leading to D/C 2 (1) 0 2 (1) 26 (1) 2 (<1) 24 (1)
Death 2 (1) 1 (10) 1 (1) 16 (<1) 4 (<1) 12 (<1)
Abbreviations: AE, adverse event; DAA, direct-acting antiviral (ombitasvir/paritaprevir/ritonavir + dasabuvir); D/C, discontinuation; HCV, hepatitis C virus; OST, opioid substitution therapy; 
RBV, ribavirin.
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lower in patients receiving OST compared with those not receiv-
ing OST. Treatment was also well tolerated. This study provides 
additional data to support DAA treatment for people receiving 
OST, consistent with international guidelines [23–26].
Overall, 97% of people receiving OST completed therapy in 
this study, which was similar to the response in those not receiv-
ing OST (98%). These data are also consistent with other post 
hoc studies demonstrating that 96%–97% of people receiving 
OST and DAA therapy completed therapy in phase III clin-
ical trials of sofosbuvir/ledipasvir and sofosbuvir/velpatasvir 
[7, 8]. This is also similar to data from a large phase III study of 
elbasvir/grazoprevir therapy, in which 99% of patients receiving 
opioid agonist therapy completed DAA therapy, perhaps fur-
ther facilitated by the use of a daily adherence reminder [11]. 
Despite a high proportion of people completing HCV therapy, 
adherence in the present analysis was significantly lower among 
people receiving OST than in those not receiving OST (88% vs 
97%). The proportion of people with genotype 1a who received 
ribavirin was higher among those receiving OST compared 
with those not receiving OST. As such, it may be possible still 
that the lower adherence in the OST group was partly driven by 
the larger proportion of genotype 1a participants who received 
ribavirin as compared with those not receiving OST.
Although adherence to therapy was lower for people receiv-
ing OST, there was no difference in SVR12 between those receiv-
ing and not receiving OST. The 94% SVR12 among people who 
received ombitasvir/paritaprevir/ritonavir and dasabuvir with 
or without ribavirin is similar to other clinical trials of DAA 
therapy achieving responses of 92%–96% in people receiv-
ing stable OST, with no differences observed between people 
receiving and not receiving OST [7, 8, 11]. Data from a large 
registry of real-world data from Germany demonstrated an SVR 
of 85% (n  =  528) in people receiving OST and DAA therapy 
compared with 91% in those not receiving OST (n = 5582) [27]. 
The major reason for not attaining SVR was not viral relapse 
(2% OST vs 4% no OST) but loss to follow-up between the end 
of treatment and SVR12 (8% OST vs 2% no OST) [27]. This 
issue of loss to follow-up between end of treatment and SVR12 
has also been observed in real-world studies among people 
with a history of injecting drug use treated with DAA thera-
pies [28–30]. However, given that these individuals completed 
treatment and attained an end-of-treatment response, it is 
highly likely that they would have attained an SVR. Differences 
in loss to follow-up were not observed between the OST and 
non-OST populations in the present analysis because patients 
with missing SVR12 data were low in both groups (2% [3/149] 
and 1% [48/4598], respectively). Treatment was also well toler-
ated in this study. Collectively, these data provide further sup-
port for the integration of DAA therapy in settings that provide 
co-location of OST services, given the high response to therapy 
in people stable on OST in this study.
Despite international recommendations that support HCV 
therapy among people receiving OST [23–26], there are still 
some clinicians who remain reluctant to provide HCV treat-
ment to people receiving OST based on concerns of adherence, 
response to therapy, and re-infection. In the United States in 
2014, 88% of US state Medicaid committees had restrictions for 
the reimbursement of therapy for people who have used illicit 
drugs or alcohol or are receiving OST from DAA-based ther-
apy (irrespective of disease stage) [3]. As such, the data from 
this study are important to continue to build the evidence 
base to demonstrate that DAA therapy is effective in people 
receiving OST.
This study has a number of limitations. First, people with 
ongoing drug use were excluded from participating in these 
clinical trials. As such, the enrolled participants represent 
a selected population likely very engaged in care, and these 
findings cannot be generalized to other populations of people 
receiving OST who may be injecting drugs. Participants receiv-
ing OST were initially excluded from the phase III program 
and were evaluated separately in a phase IIb pilot study. People 
receiving OST were eligible for inclusion in phase III/IIIb stud-
ies following preliminary data demonstrating an SVR of 97% 
in a pilot study of 38 people receiving methadone or buprenor-
phine and ombitasvir/paritaprevir/ritonavir plus dasabuvir and 
ribavirin. Second, this is a post hoc analysis of phase III clin-
ical trials, and this study was not specified before starting these 
clinical trials. Third, given that people receiving OST were less 
likely to return their pill bottles, a lower proportion of people 
receiving OST had available data on adherence compared with 
those not receiving OST (81% vs 91%, respectively). As such, it 
is possible that adherence to therapy among those on OST was 
overestimated in this study and there was a larger difference in 
adherence compared with those not receiving OST. However, 
irrespective of these limitations, these data are important to 
publish to add to the body of peer-reviewed evidence demon-
strating that people on stable OST can be successfully treated 
with DAA therapy.
Table 4. Adverse Events Occurring in ≥10% of Patients With Chronic HCV 
Genotype 1 Receiving Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir 
With or Without Ribavirin, Stratified by Receipt of Opioid Substitution 
Therapy
No. (%) Receiving OST (n = 149)
Not Receiving OST
(n = 4598)
Fatigue 41 (28) 1264 (28)
Headache 29 (20) 1035 (23)
Nausea 39 (26) 690 (15)
Pruritus 17 (11) 560 (12)
Insomnia 21 (14) 547 (12)
Diarrhea 10 (7) 466 (10)
Rash 15 (10) 276 (6)
Anxiety 16 (11) 172 (4)
Abbreviations: HCV, hepatitis C virus; OST, opioid substitution therapy.
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In conclusion, these data demonstrate that ombitasvir/parita-
previr/ritonavir and dasabuvir with or without ribavirin is well 
tolerated and effective in people receiving OST, despite a lower 
adherence to therapy compared with people not receiving OST. 
Further international trials are underway to evaluate DAA ther-
apy in people receiving OST and recent PWID with ombitasvir/
paritaprevir/ritonavir and dasabuvir with or without ribavirin 
(D3FEAT, NCT02498015) and sofosbuvir/velpatasvir for recent 
PWID (SIMPLIFY, NCT02336139; HERO, NCT02824640); these 
trials should provide further data in this regard. These data will 
be crucial for expanding access to testing, care, and treatment for 
PWID and achieving HCV elimination in this priority population.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility of 
the authors, so questions or comments should be addressed to the corre-
sponding author.
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